NVS Stock Recent News
NVS LATEST HEADLINES
Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The agreed deal is fully in line with the therapeutic area focus of Novartis and leverages our strength and expertise in renal disease.
Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion Transaction is expected to be completed in the second half of 2025, subject to customary closing conditions SAN DIEGO , April 30, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into an agreement and plan of merger with Novartis AG ("Novartis") and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will acquire Regulus for an initial payment of $7.00 per share in cash at closing, or $0.8 billion. The upfront cash portion of the consideration represents a premium of 274 percent to Regulus' 60-day volume-weighted average stock price and 108 percent to Regulus
Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings.
Vasant Narasimhan, Novartis CEO, discusses the impact of potential tariffs.
Novartis AG (NYSE:NVS ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants Simon Baker - Redburn Atlantic Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Florent Cespedes - Bernstein Peter Verdult - BNP Paribas Exane Richard Vosser - JPMorgan James Quigley - Goldman Sachs Thibault Boutherin - Morgan Stanley Matthew Weston - UBS Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Steve Scala - TD Securities Operator Good morning and good afternoon, and welcome to the Novartis Q1 2025 Results Release Conference Call and Live Webcast. [Operator Instructions] A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends.
Novartis CEO on earnings: Launch drivers like breast cancer, MS medicines are performing really well
Vasant Narasimhan, Novartis CEO, joins 'Money Movers' to discuss the company's quarterly earnings results.
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance.
Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year guidance. Net sales were up 15% on a constant currency basis to $13.2 billion, compared to the $13.12 billion estimated by analysts in an LSEG poll.